Abbott Labs Puts Active After Q4 Earnings
Shares in Abbott Laboratories (Ticker: ABT) are in negative territory on Wednesday after the company reported better than expected fourth-quarter earnings, but revenue that was less than analysts estimated. Shares in the medical products company dropped 5.5% to an intraday low of $36.94 near the open, but have rallied significantly during the session to stand at $38.40 as of the time of this writing.
Options changing hands on Abbott Labs in the early going suggests some traders are positioning for the price of the underlying to potentially extend losses this week. The 24 Jan ?14 weekly puts traded more than 1,600 times this morning against open interest of 204 contracts. Time and sales data indicates most of the volume was purchased for an average premium of $0.45 each. Put buyers stand ready to profit at expiration this week in the event that ABT shares slip 2.2% from the current level of $38.40 to breach the breakeven point on the downside at $37.55.
The regular Mar $37 strike puts attracted fresh interest as well during the first half of the session, with around 440 contracts purchased at a premium of $0.74 each. These puts make money if shares move 5.5% lower to trade below $36.26 by March expiration. Put options are more active than calls on Abbott this morning, with the put/call ratio hovering near 1.4 just before midday in New York trading.?
———————————————————————————————–
Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither Interactive Brokers LLC nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither IB nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance is not necessarily indicative of future results.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.